SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Mechanism: neuroinflammation-ad-pd-als

mechanism 2,818 words KG: ent-phen-69654b86

Contents

neuroinflammation-ad-pd-als

⚙ Mechanism Info

Name	ent-phen-69654b86

Knowledge Graph

Related Hypotheses (30)

SASP-Mediated Complement Cascade Amplification
Score: 0.70 TREM2-mediated microglial tau clearance enhancement
Score: 0.49 Microbial Inflammasome Priming Prevention
Score: 0.58 Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68 Vagal Afferent Microbial Signal Modulation
Score: 0.52

Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.50 Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53 APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54 Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59 TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41 Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51 Optogenetic Microglial Deactivation via Engineered Inhibitor
Score: 0.38 Competitive APOE4 Domain Stabilization Peptides
Score: 0.56 Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44 Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46 Vocal Cord Neuroplasticity Stimulation
Score: 0.50 TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64 TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61 Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60 TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming
Score: 0.59 Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53 Synaptic Pruning Precision Therapy
Score: 0.47 Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47 TREM2-Dependent Microglial Senescence Transition
Score: 0.69 Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam
Score: 0.62 Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.55 Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52 Orexin-Microglia Modulation Therapy
Score: 0.49 APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49

Related Analyses (30)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed

How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed What are the molecular signatures that distinguish protectiv
neurodegeneration · failed RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Synaptic pruning by microglia in early AD
neurodegeneration · archived Circuit-level neural dynamics in neurodegeneration
neuroscience · archived Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived

Related Experiments (30)

Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40 s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice
falsification · proposed · Score: 0.40 s:** - GPR32 knockout in microglia should worsen neuroinflam
falsification · proposed · Score: 0.40 Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40 s:** - ALOX15 overexpression in healthy astrocytes should be
falsification · proposed · Score: 0.40

s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Proposed experiment from debate on Microglia activate astroc
falsification · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40 Microglial Contributions to Huntington's Disease Pathogenesi
validation · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40 Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40

SciDEX — scidex.ai — Dashboard | Atlas